Eiger BioPharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2011
Net Income	-74.96	-74.96	-96.78	-33.92	-65.05	-70.25	Upgrade
Depreciation & Amortization	0.75	0.75	0.84	0.8	0.65	0.49	Upgrade
Share-Based Compensation	5.01	5.01	8.32	7.9	5.97	5.68	Upgrade
Other Operating Activities	-5.34	-5.34	4.61	-46.13	-4.75	0.47	Upgrade
Operating Cash Flow	-74.55	-74.55	-83.01	-71.34	-63.19	-63.61	Upgrade
Capital Expenditures	-0.23	-0.23	-0.34	0.06	-0.26	-0.48	Upgrade
Change in Investments	74.46	74.46	9.97	14.98	-44.53	-16	Upgrade
Other Investing Activities	-	-	-	46.49	-	-	Upgrade
Investing Cash Flow	74.23	74.23	9.63	61.53	-44.79	-16.47	Upgrade
Share Issuance / Repurchase	0.06	0.06	71.56	3.3	96.97	53.32	Upgrade
Debt Issued / Paid	0	0	5.45	-0.18	0	4.05	Upgrade
Other Financing Activities	-0.02	-0.02	-0.05	0.05	0.5	0.83	Upgrade
Financing Cash Flow	0.04	0.04	76.96	3.17	97.46	58.2	Upgrade
Exchange Rate Effect	-0.08	-0.08	0	0	0	0	Upgrade
Net Cash Flow	-0.36	-0.36	3.58	-6.64	-10.51	-21.89	Upgrade
Free Cash Flow	-74.78	-74.78	-83.35	-71.29	-63.44	-64.09	Upgrade
Free Cash Flow Margin	-474.11%	-474.11%	-618.14%	-587.10%	-	-	Upgrade
Free Cash Flow Per Share	-50.66	-50.66	-60.07	-63.00	-67.63	-84.38	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).